Literature DB >> 12715206

B-cell lymphopenia and hypogammaglobulinemia in thymoma patients.

L Montella1, A M Masci, G Merkabaoui, F Perna, L Vitiello, L Racioppi, G Palmieri.   

Abstract

Thymic tumors represent a unique neoplastic disease associated with various immune-mediated syndromes. Immune impairment is generically recognized to be associated with thymoma. Hypogammaglobulinemia and recurrent pulmonary infections in thymoma patients define Good's syndrome. Apart from sporadic reports focusing on this topic, there is still a lack of knowledge on immune assessment and clinical sequelae in thymoma patients. The present study was performed to evaluate immunoglobulin levels, CD19(+) B lymphocytes, and CD3(+) T lymphocytes in a large series of thymoma patients from a single institution. The occurrence of recurrent severe infections was related to immunological findings to identify the possible correlation with the immunodeficiency status. Eighteen patients (eight males, ten females, mean age: 56 years, range: 19-75) with a pathological diagnosis of thymic tumor were studied. Six patients suffered from clinical recurrent pulmonary infections. Blood samples were collected to measure serum immunoglobulins and analyze immunophenotype. Low T lymphocyte number was found in 22% of the patients. T lymphocytosis was present in one patient. Panhypogammaglobulinemia was found in 4 of 18 patients (22%). Conversely B lymphopenia was a frequent finding in this series of thymoma patients (9 of 18, 50%). Five of six patients (83%) with recurrent infections had B lymphopenia, while only two (33%) had panhypogammaglobulinemia. B lymphopenia often occurred in this series of thymoma patients and was related to susceptibility to recurrent infections more than hypogammaglobulinemia. Therefore, immunophenotype has to be monitored in follow-up of thymoma patients because it may reveal significant abnormalities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715206     DOI: 10.1007/s00277-003-0635-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  8 in total

Review 1.  Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.

Authors:  Theodoros Kelesidis; Otto Yang
Journal:  Clin Immunol       Date:  2010-02-10       Impact factor: 3.969

2.  Cytomegalovirus retinitis in Good syndrome: case report and review of literature.

Authors:  Magdalena Popiela; Mohan Varikkara; Zachariah Koshy
Journal:  BMJ Case Rep       Date:  2009-06-21

Review 3.  Thymoma and immunodeficiency (Good syndrome): a report of 2 unusual cases and review of the literature.

Authors:  Shradha Agarwal; Charlotte Cunningham-Rundles
Journal:  Ann Allergy Asthma Immunol       Date:  2007-02       Impact factor: 6.347

4.  Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Authors:  Sukhmani K Padda; Xiaopan Yao; Alberto Antonicelli; Jonathan W Riess; Yue Shang; Joseph B Shrager; Robert Korst; Frank Detterbeck; James Huang; Bryan M Burt; Heather A Wakelee; Sunil S Badve
Journal:  J Thorac Oncol       Date:  2017-11-27       Impact factor: 15.609

5.  Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Authors:  Andrew L Mammen; Arun Rajan; Katherine Pak; Tanya Lehky; Livia Casciola-Rosen; Renee N Donahue; Lauren M Lepone; Anastasia Zekeridou; Sean J Pittock; Raffit Hassan; Jeffrey Schlom; James L Gulley
Journal:  Ann Rheum Dis       Date:  2018-09-05       Impact factor: 19.103

6.  Paraneoplastic syndromes in thymoma: an immunological perspective.

Authors:  Robert P Nelson; Robert M Pascuzzi
Journal:  Curr Treat Options Oncol       Date:  2009-02-06

Review 7.  How to interpret and pursue an abnormal complete blood cell count in adults.

Authors:  Ayalew Tefferi; Curtis A Hanson; David J Inwards
Journal:  Mayo Clin Proc       Date:  2005-07       Impact factor: 7.616

Review 8.  The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Authors:  Liliana Montella; Margaret Ottaviano; Rocco Morra; Erica Pietroluongo; Pietro De Placido; Marianna Tortora; Chiara Sorrentino; Gaetano Facchini; Sabino De Placido; Mario Giuliano; Giovannella Palmieri
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.